Expert Review of Pharmacoeconomics & Outcomes Research最新文献_第5页

Cost-effectiveness of atezolizumab plus bevacizumab as first-line therapy for metastatic renal cell carcinoma. 阿特珠单抗联合贝伐单抗作为转移性肾细胞癌一线疗法的成本效益。

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-02-01 Epub Date: 2024-09-01 DOI: 10.1080/14737167.2024.2399246

Siying Wang, Ouyang Xie, Meiyu Wu, Heng Xiang, Chongqing Tan, Xiaomin Wan

{"title":"Cost-effectiveness of atezolizumab plus bevacizumab as first-line therapy for metastatic renal cell carcinoma.","authors":"Siying Wang, Ouyang Xie, Meiyu Wu, Heng Xiang, Chongqing Tan, Xiaomin Wan","doi":"10.1080/14737167.2024.2399246","DOIUrl":"10.1080/14737167.2024.2399246","url":null,"abstract":"Objectives: Recently, the IMmotion151 trial evaluated the safety and efficacy of atezolizumab plus bevacizumab in metastatic renal cell carcinoma (mRCC) and found that this combination led to longer progression-free survival. However, no studies have evaluated the cost-effectiveness of atezolizumab plus bevacizumab.Methods: We constructed a Markov model to evaluate the cost-effectiveness of atezolizumab plus bevacizumab, using costs and utilities from the published studies. We set the willingness-to-pay (WTP) threshold at $150,000. One-way and probabilistic sensitivity analyses were performed to ensure that our results were robust. We performed a threshold analysis to explore a more appropriate price for atezolizumab.Results: Our results found that although atezolizumab plus bevacizumab provided more quality-adjusted life years (QALYs), its incremental cost-effectiveness ratio (ICER) was $1,640,532/QALY, well above the WTP threshold. One-way and probabilistic sensitivity analysis results confirmed the robust of this conclusion. Based on the threshold analysis, for atezolizumab plus bevacizumab to be cost-effective, the price of them would need to be reduced by 46.3% or more.Conclusions: From the perspective of US payers, atezolizumab plus bevacizumab is not cost-effective for mRCC patients. To make this combination cost-effective in the future, the price of atezolizumab and bevacizumab needs to be reduced.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"173-178"},"PeriodicalIF":1.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142105922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

How can patients shape digital medicine? A rapid review of patient and public involvement and engagement in the development of digital health technologies for neurological conditions. 患者如何塑造数字医学？快速回顾患者和公众参与神经系统疾病数字医疗技术开发的情况。

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-02-01 Epub Date: 2024-10-07 DOI: 10.1080/14737167.2024.2410245

Megan Hanrahan, Cameron Wilson, Alison Keogh, Sandra Barker, Lynn Rochester, Katie Brittain, Jack Lumsdon, Ríona McArdle

{"title":"How can patients shape digital medicine? A rapid review of patient and public involvement and engagement in the development of digital health technologies for neurological conditions.","authors":"Megan Hanrahan, Cameron Wilson, Alison Keogh, Sandra Barker, Lynn Rochester, Katie Brittain, Jack Lumsdon, Ríona McArdle","doi":"10.1080/14737167.2024.2410245","DOIUrl":"10.1080/14737167.2024.2410245","url":null,"abstract":"Introduction: Patient and Public Involvement and Engagement (PPIE) involves working 'with' or 'by' patients and the public, rather than 'to,' 'about,' or 'for' them, and is integral to neurological and digital health research. This rapid review examined PPIE integration in the development and implementation of digital health technologies for neurological conditions.Methods: Key terms were input into six databases. Included articles were qualitative studies or PPIE activities involving patient perspectives in shaping digital health technologies for neurological conditions. Bias was evaluated using the NICE qualitative checklist, with reporting following PRISMA guidelines.Results: 2,140 articles were identified, with 28 included. Of these, 25 were qualitative studies, and only three were focused PPIE activities. Patient involvement was mostly limited to one-off consultations during development.There was little evidence of PPIE during implementation, and minimal reporting on its impact.Conclusions: PPIE has been inconsistently reported in this research area, highlighting the need for more guidance and best-practice examples This review used a UK-based definition of PPIE, which may have excluded relevant activities from other countries. Future reviews should broaden terminology to capture PPIE integration globally.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"137-154"},"PeriodicalIF":1.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11789707/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142389151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Estimated value of productivity lost due to childhood chickenpox in the United Kingdom: a survey of parents. 英国儿童水痘造成的生产力损失估计值：一项对家长的调查。

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-02-01 Epub Date: 2024-11-22 DOI: 10.1080/14737167.2024.2410257

Raphael Wittenberg, Jacqueline Damant, Amritpal Rehill, Martin Knapp, Tobi Adeyemi, Ian Matthews

{"title":"Estimated value of productivity lost due to childhood chickenpox in the United Kingdom: a survey of parents.","authors":"Raphael Wittenberg, Jacqueline Damant, Amritpal Rehill, Martin Knapp, Tobi Adeyemi, Ian Matthews","doi":"10.1080/14737167.2024.2410257","DOIUrl":"10.1080/14737167.2024.2410257","url":null,"abstract":"Background: While medical costs of chickenpox have been researched, little is known about indirect costs. Understanding total costs is important for decisions about vaccination. This study estimated the value of lost productivity of adults missing work to care for children with chickenpox.Research design and methods: It comprised an international literature review, an online survey of 1,526 parents of children aged 1-11 years, and computation of indirect costs of chickenpox in the UK. The survey covered chickenpox episodes amongst respondents' children, time children took off school/nursery, and work absenteeism by parents/caregivers caring for them.Results: Respondents reported on 2,283 children, of whom 52% (1185/2283) experienced chickenpox. Almost half (591/1185) missed days of school/nursery, averaging 5.6 days missed. In 260 cases of 542 adults providing data with such a child, an adult missed work to care for the child. The daily value of this lost productivity was £170. There were approximately 200,000 GP consultations for chickenpox and 625,000 births annually, suggesting the annual chickenpox incidence lies between these figures. The estimated annual UK productivity loss due to chickenpox is £20-£70 million ($25-$90 million).Conclusions: Annual value of lost productivity due to chickenpox is in range £20 to £70 million.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"197-203"},"PeriodicalIF":1.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142344401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of patient's financial burden of COVID-19 treatment on antiviral prescription rates and clinical and economic outcomes. 患者治疗 COVID-19 的经济负担对抗病毒处方率以及临床和经济结果的影响。

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-02-01 Epub Date: 2024-10-04 DOI: 10.1080/14737167.2024.2410963

Mitsuhiro Nagano, Sachiko Hyokai, Kanae Togo, Tendai Mugwagwa, Akira Yuasa

{"title":"Impact of patient's financial burden of COVID-19 treatment on antiviral prescription rates and clinical and economic outcomes.","authors":"Mitsuhiro Nagano, Sachiko Hyokai, Kanae Togo, Tendai Mugwagwa, Akira Yuasa","doi":"10.1080/14737167.2024.2410963","DOIUrl":"10.1080/14737167.2024.2410963","url":null,"abstract":"Background: In Japan, medical expenses for COVID-19 treatment transitioned from full public funding support to out-of-pocket (OOP) payment by patients plus partial public support in October 2023, and public support fully ended in March 2024. This study evaluated the clinical and economic impacts of initiating OOP payments.Research design and methods: To assess the impact on prescription rates, we compared the prescription rates of antivirals from the 4-month pre- to post-OOP payment initiation period using a claims database. Subsequently, a budget impact model assessed the impacts of a hypothetical decline in the prescription rates on COVID-19-related hospitalizations, deaths, and direct medical costs for antiviral prescription and hospitalization.Results: The antiviral prescription rate per 100 patients decreased from 17.5 for the pre-OOP payment initiation period to 11.5 for the post-OOP payment initiation period, that is, a change of - 34.3%. With prescription rate decreases of 40%, 60%, and 80%, the hospitalizations would increase annually by 22,533 (3.3%), 33800 (5.0%), and 45,066 (6.6%), respectively. The total costs would increase by JPY9.5 billion (USD67.3 million; 0.7%), JPY14.3 billion (USD100.9 million; 1.0%), and JPY19.0 billion (USD134.5 million; 1.3%), respectively.Conclusions: Higher OOP payment decreased the antiviral prescription rate, potentially leading to clinical and economic loss.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"215-225"},"PeriodicalIF":1.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142344402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Perceptions of risk sharing agreements in South Korea from the viewpoints of key stakeholders: a convergent parallel mixed approach. 从主要利益相关者的观点看韩国对风险分担协议的看法：一种趋同平行混合方法。

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-02-01 Epub Date: 2024-09-30 DOI: 10.1080/14737167.2024.2410250

Tae-Jin Lee, Kyung-Bok Son

{"title":"Perceptions of risk sharing agreements in South Korea from the viewpoints of key stakeholders: a convergent parallel mixed approach.","authors":"Tae-Jin Lee, Kyung-Bok Son","doi":"10.1080/14737167.2024.2410250","DOIUrl":"10.1080/14737167.2024.2410250","url":null,"abstract":"Objectives: In 2013, South Korea introduced risk-sharing agreements (RSAs) as a new reimbursement mechanism to enhance access to new medicines and to manage pharmaceutical expenditures. This study evaluates RSAs in South Korea from the viewpoints of key stakeholders.Methods: In 2022, a survey and semi-structured interviews were conducted. Study participants were recruited from academia (n = 3), domestic (n = 4) and foreign (n = 6) manufacturers, and government agencies (n = 6) using a purposive sampling method.Results: Key stakeholders perceived the objective of RSAs to be 'access to medicines' and understood RSAs to manage uncertainty about 'expenditures.' They responded that financial- and performance-based RSAs address uncertainty about 'expenditures' and 'clinical effectiveness,' respectively. All stakeholders agreed that RSAs have increased the likelihood that new medicines will be listed and have reduced out-of-pocket expenditures for patients. However, foreign manufacturers insisted that the benefits of RSAs are marginal, while the administrative burden on manufacturers is high.Conclusion: The gaps in perception between stakeholders could be narrowed by conducting a comprehensive evaluation. Financial- and performance-based RSAs need to be clearly distinguished and aligned to address the uncertainties of a new medicine in health systems.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"235-243"},"PeriodicalIF":1.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142344417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cost-effectiveness of first-line sintilimab plus chemotherapy versus chemotherapy for advanced esophageal carcinoma in China. 中国晚期食管癌一线辛替利单抗加化疗与化疗的成本效益对比。

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-02-01 Epub Date: 2024-09-30 DOI: 10.1080/14737167.2024.2410248

Nanlong Lin, Shiting Chen, Zhiwei Zheng, Xiaobing Song

引用次数: 0

Time from approval to reimbursement recommendations in healthcare systems with centralized HTA processes. Focus on the Polish HTA agency. 采用集中式 HTA 流程的医疗系统从批准到提出报销建议所需的时间。重点关注波兰的 HTA 机构。

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-02-01 Epub Date: 2024-10-21 DOI: 10.1080/14737167.2024.2416240

Aneta Mela, Andrzej Tysarowski, Elżbieta Rdzanek, Tomasz Blicharski, Janusz Jaroszyński, Marzena Furtak-Niczyporuk, Karina Jahnz-Różyk, Maciej Niewada

{"title":"Time from approval to reimbursement recommendations in healthcare systems with centralized HTA processes. Focus on the Polish HTA agency.","authors":"Aneta Mela, Andrzej Tysarowski, Elżbieta Rdzanek, Tomasz Blicharski, Janusz Jaroszyński, Marzena Furtak-Niczyporuk, Karina Jahnz-Różyk, Maciej Niewada","doi":"10.1080/14737167.2024.2416240","DOIUrl":"10.1080/14737167.2024.2416240","url":null,"abstract":"Background: To analyze the time from drug registration to reimbursement recommendations, we examined medicinal products, including new clinical indications, registered by the EMA between 2014 and 2019 across various therapeutic areas.Materials and methods: The Polish Agency for Health Technology Assessment and Tariffication (AOTMiT) was compared with 11 agencies in England, Wales, Ireland, Scotland, the Netherlands, Norway, France, Germany, New Zealand, Canada, Australia. A total of 1,942 recommendations published by 12 HTA agencies were analyzed.Results: The time from registration to recommendation in Poland was statistically significantly longer than for the other countries. The analysis revealed noticeable differences in the time it takes from drug registration to recommendation across the countries included in this analysis. Analyzing trends from 2014 to 2019 across individual countries, there appears to be a slight tendency toward a decrease in the median time from registration to recommendation in many agencies.Conclusions: This may suggest improvements in the processes of the recommending authorities and the companies responsible for providing data for assessment. Despite Poland having one of the longest times from registration to recommendation among the countries analyzed, there has been a clear year-over-year decrease in the time to publication of reimbursement recommendations.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"265-273"},"PeriodicalIF":1.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142461507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Enhancing pharmacist intervention targeting based on patient clustering with unsupervised machine learning. 基于无监督机器学习的患者聚类，提高药剂师干预的针对性。

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-02-01 Epub Date: 2024-09-23 DOI: 10.1080/14737167.2024.2406810

Chi Chun Steve Tsang, Junling Wang

{"title":"Enhancing pharmacist intervention targeting based on patient clustering with unsupervised machine learning.","authors":"Chi Chun Steve Tsang, Junling Wang","doi":"10.1080/14737167.2024.2406810","DOIUrl":"10.1080/14737167.2024.2406810","url":null,"abstract":"Objectives: Adherence to the American Diabetes Association (ADA) Standards of Medical Care is low. This study aimed to assist pharmacists in identifying patients for diabetes control interventions using unsupervised machine learning.Methods: This study analyzed the 2021 Medical Expenditure Panel Survey and used a k-mode cluster analysis. Patient features analyzed were adherence to a select set of preventive measures from the ADA Standards of Medical Care (HbA1c test, foot examination, blood cholesterol test, dilated eye examination, and influenza vaccination) and some patient characteristics (age, gender, health insurance, insulin use, and diabetes-related complications).Results: The study included 1,219 patients with self-reported diabetes, and the adherence rate to the ADA standards was 33.72%. Five distinct clusters emerged: (A) moderate-complexity, privately insured male; (B) moderate-complexity, publicly insured female; (C) low-complexity, privately insured female; (D) high-complexity, publicly insured female; (E) moderate-complexity, publicly insured male. Groups B, C, and E exhibited nonadherence.Conclusions: Pharmacists can target publicly insured elderly (Groups B and E) and privately insured middle-aged females (Group C) for interventions. For instance, pharmacists may help patients in Groups B and E locate existing resources in their insurance program and remind those in Group C of the importance of adequate diabetes care.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"187-195"},"PeriodicalIF":1.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11786995/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142282664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A methodological guide for implementing and interpreting results of probabilistic analysis. 实施和解释概率分析结果的方法指南。

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-02-01 Epub Date: 2024-10-21 DOI: 10.1080/14737167.2024.2416255

Xuanqian Xie, Alexis K Schaink, Olga Gajic-Veljanoski, Man Wah Yeung, Myra Wang, Chunmei Li, Wendy J Ungar

{"title":"A methodological guide for implementing and interpreting results of probabilistic analysis.","authors":"Xuanqian Xie, Alexis K Schaink, Olga Gajic-Veljanoski, Man Wah Yeung, Myra Wang, Chunmei Li, Wendy J Ungar","doi":"10.1080/14737167.2024.2416255","DOIUrl":"10.1080/14737167.2024.2416255","url":null,"abstract":"Introduction: Probabilistic analysis, also referred to as probabilistic sensitivity analysis (PSA), is used extensively in cost-effectiveness evaluations of health technologies. We present methodological guidance for implementing probabilistic analysis and interpreting its results for policy and decision-making.Methods: We review the methodological issues related to common practices in probabilistic analysis, explore aspects that are currently not widely addressed in the health economics literature, and provide an overview of recent methodological developments.Results: We use examples to highlight the advantages and disadvantages of common tools used for presenting probabilistic analysis results, including the cost-effectiveness acceptability curve (CEAC), cost-effectiveness acceptability frontier (CEAF), and value of information (VOI) analysis. We raise and address issues related to using Monte Carlo standard error to determine the number of iterations required, the implications of large uncertainty, and the credibility and meaningfulness of small differences in quality-adjusted life-years (QALYs). We then discuss evolving methods in probabilistic analysis, cautious uses of probabilistic analysis, and factors impacting parameter uncertainty.Conclusions: A deeper understanding of probabilistic analysis methods enables health economists and decision-makers to more effectively address and interpret parameter uncertainty in health economic evaluations, which is essential for making informed policy decisions.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"123-135"},"PeriodicalIF":1.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142461493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Budget impact of low-dose computed tomography screening for lung cancer in Argentina.

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-01-30 DOI: 10.1080/14737167.2025.2460523

Constanza Silvestrini, Lucas Perelli, Andrea Alcaraz, Natalia Espinola, Fernando Argento

{"title":"Budget impact of low-dose computed tomography screening for lung cancer in Argentina.","authors":"Constanza Silvestrini, Lucas Perelli, Andrea Alcaraz, Natalia Espinola, Fernando Argento","doi":"10.1080/14737167.2025.2460523","DOIUrl":"10.1080/14737167.2025.2460523","url":null,"abstract":"Background: Lung cancer (LC) is a leading cause of cancer mortality in Argentina. Low-dose computed tomography (LDCT) had demonstrated higher efficacy than chest radiography as a screening method for early detection and reducing LC mortality. This study estimates the Budget Impact of implementing annual LDCT screening for individuals aged 55-74 with at least 30 pack-years of smoking in Argentina.Research design and methods: A budgetary impact model for a dynamic cohort was developed from the Argentine health system's perspective, accounting for LC incidents, prevalents and death probability, distinguishing by disease stage and survival years. Model parameters were sourced from literature and official databases, with costs expressed in 2023 USD.Results: In Argentina, 726,420 individuals were eligible for annual LC screening. The average annual budget was USD 196,611,452 in the current scenario and USD 207,439,560 in the projected scenario, leading to a 5.20% incremental cost due to more false positives in LDCT and screening costs. The budget impact per member per month was USD 0.019, slightly above the estimated threshold of USD 0.015.Conclusions: The introduction of LDCT for LC screening increased the health system budget in Argentina but improved early disease detection.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-8"},"PeriodicalIF":1.8,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143058480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0